Daily11h
Dapagliflozin prevents renal injury by improving mitochondrial function and reducing oxidative stress in diabetes patients: Study
China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...
Breakthrough medication significantly cuts risk of heart attacks and strokes: Lancet study
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
Science Daily20h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Monthly Prescribing Reference23h
Study Investigates Whether and When to Stop Metformin in Advanced CKD
Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.